A recently granted patent (Publication Number: US11912759B2) discloses an antibody designed to bind to human transthyretin. The antibody comprises specific amino acid sequences in its heavy chain variable region and light chain variable region. The patent claims cover various aspects of the antibody, including its isotype (IgG1, IgG2, or IgG4), structure (intact antibody or binding fragment), fusion with constant regions, and mutant forms for reduced binding to Fc? receptors. Additionally, the patent includes claims related to pharmaceutical compositions containing the antibody, nucleic acids encoding the antibody's heavy and light chains, recombinant expression vectors, host cells transformed with the vectors, and methods for producing and using the antibody.
Furthermore, the patent claims encompass methods for treating transthyretin-mediated amyloidosis in a subject by administering the antibody. It also extends to treating various conditions such as cardiomyopathy, familial amyloid polyneuropathy, central nervous system selective amyloidosis, osteoarthritis, rheumatoid arthritis, and age-related macular degeneration with the antibody. The patent provides a comprehensive coverage of the antibody's design, production, and therapeutic applications, highlighting its potential in addressing a range of diseases and disorders associated with transthyretin and beyond.
